首页 正文

JI017 Sensitizes EGFR-T790M NSCLC to Erlotinib by Extinguishing the STAT3-Survivin Axis

{{output}}
IntroductionFirst-generation EGFR-TKIs in NSCLC frequently lose efficacy as a result of the secondary EGFR-T790M mutation and a "persistent-STAT3" prosurvival pathway that sustains STAT3-survivin signaling in the face of EGFR inhibition. Preclinical evidence... ...